Anavex Life Sciences Corp (AVXL)

[jimmy667]

I do not think you are missing anything. One would assume if they are showing continued improvement the patients would want to continue on the optimized dosing regimen as well as the Doctors tending to the patients and the Company.
One possible senareo is that it may be planned the these remaining 30 patients become part of the 300 plus cohort for the Phase 2/3 pivotal study. Which has not been announced but has been announced that AVXL will go forward with that study. It could be that it is not decided yet as of yet if they will or will not part of that cohort. If they will be then extension of current study would be moot. If it is decided they will not then maybe they can seek compassionate use or extension. So you may get your answer in conjuntion with the announcement of the pivotal study.
Also there maybe a logistics and supply issue in that one would suppose that they do not have a huge supply on the shelf. For the Phase 2/3 the Company must arrange for contract manufacturing of at least 10X of current capacity.
I think your concern is valid but I believe it will be resolved positively.
From a purely paranoid share price perspective if they announce extension before the announcing the Phase 2/3 the market participants may react negatively as a sign there will be a delay in starting that next study. This whole subject might be a clue that the Phase 2/3 announcement will come soon.
I do not have much knowledge in this arena just trying to view the issue from all angles.
Good Luck to all and God Bless all and especially the important work that is being done by the Company and it's independent researchers and of course the patients themselves.